Is Pharmacogenetic Panel Testing Applicable to Low-Dose Methotrexate in Rheumatoid Arthritis? – A Case Report

PURPOSE: Pharmacogenetic (PGx) panel testing could help to determine the heritable component of a rheumatoid arthritis (RA) patient’s susceptibility for therapy failure and/or adverse drug reactions (ADRs) from methotrexate (MTX). Considering the literature mentioning the potential applicability of...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeiziner, Chiara, Allemann, Samuel S, Hersberger, Kurt E, Meyer zu Schwabedissen, Henriette E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109898/
https://www.ncbi.nlm.nih.gov/pubmed/35586477
http://dx.doi.org/10.2147/PGPM.S354011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109898/
https://www.ncbi.nlm.nih.gov/pubmed/35586477
http://dx.doi.org/10.2147/PGPM.S354011

Ejemplares similares